1090 related articles for article (PubMed ID: 34022684)
1. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade opens a new way to cancer immunotherapy.
Sadreddini S; Baradaran B; Aghebati-Maleki A; Sadreddini S; Shanehbandi D; Fotouhi A; Aghebati-Maleki L
J Cell Physiol; 2019 Jun; 234(6):8541-8549. PubMed ID: 30511409
[TBL] [Abstract][Full Text] [Related]
3. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Rotte A; Jin JY; Lemaire V
Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
[TBL] [Abstract][Full Text] [Related]
5. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Lee JB; Ha SJ; Kim HR
Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
[TBL] [Abstract][Full Text] [Related]
6. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
7. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
8. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
Wang L; Bai L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
[TBL] [Abstract][Full Text] [Related]
9. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W; Won T; Daoud A; Čiháková D
Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
[TBL] [Abstract][Full Text] [Related]
11. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
13. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
14. Anticancer natural products targeting immune checkpoint protein network.
Chun KS; Kim DH; Raut PK; Surh YJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
Cancer Biol Med; 2024 May; ():. PubMed ID: 38801082
[TBL] [Abstract][Full Text] [Related]
16. [Next generation of anti-immune checkpoints antibodies].
Bonnefoy N; Olive D; Vanhove B
Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901
[TBL] [Abstract][Full Text] [Related]
17. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
Yadav R; Hakobyan N; Wang JC
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
[TBL] [Abstract][Full Text] [Related]
18. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
19. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
